Arrowhead, Amgen license and collaboration agreement closed

American Pharmacy News Reports | Nov 23, 2016
The agreement failed because of the early termination waiting period.
The agreement failed because of the early termination waiting period. | File image
Arrowhead Pharmaceuticals has closed the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA program.
The agreement fell through because of the early termination of the waiting period according to the Hart-Scott Rodino Antitrust Improvements Act of 1976.
More News

Mayor Muriel Bowser

State Issues Mayor Bowser urges DC residents to get screened during Breast Cancer Awareness Month Oct 17, 2025

Mayor Muriel Bowser

State Issues Mayor Bowser urges DC residents to seek breast cancer screenings during awareness month Oct 17, 2025

Chris Sain President

State Issues Registration opens for 2026 Compounding Summit in Chapel Hill Oct 17, 2025

Caroline Juran Executive Director at Virginia Board of Pharmacy

State Issues Virginia ends COVID-19 vaccine standing order for adults Oct 17, 2025

B. Douglas Hoey CEO

State Issues Pharmacy groups release guidance for state policy on pharmacist-administered vaccines Oct 16, 2025

B. Douglas Hoey CEO

State Issues NCPA partners with HealthShifts to launch national pharmacy job board Oct 14, 2025

Trending

Lenora S. Newsome, President

Over 29 million affected by health care data breaches in early 2025

Martin A Makary M.D., M.P.H.

FDA advises shift from animal-derived to synthetic thyroid drugs

Martin A. Makary Commissioner of Food and Drugs - Food and Drug Administration

FDA warns against unapproved GLP-1 drugs for weight loss

Lenora S. Newsome, President

HHS mandates removal of thimerosal from all US influenza vaccines

Lenora S. Newsome, President

ISMP reports medication error caused by confusing 'l' with '1' on e-prescription